Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics (MLTX), sold 39,120 shares at $22.04 ($862K) on 2026-06-22, disclosed to the SEC on 2026-06-23.
Scheduled sale ($862k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| MLTX | SELL | 2026-04-16 | $47K | — | Filing → |
| MLTX | SELL | 2026-04-10 | $1.7M | — | Filing → |
| MLTX | BUY | 2025-10-09 | $198K | — | Filing → |